Filing Summary
Filing identity and period: The supplied filing is Transdel Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2011, filed February 23, 2012. It is not identified as a Harrow, Inc. filing or a 2010 Q4 report; the requested company and period do not match the filing text.
Business context
Transdel was a development-stage specialty pharmaceutical company focused on topical drug delivery using its Transdel platform. Its lead candidate, Ketotransdel, is a topical ketoprofen formulation for acute localized pain. The company reported no revenue since inception and had not begun commercial operations.
Financial performance and position
- Revenue: $0 reported for 2011 and 2010; no product revenue had been generated since inception.
- Loss: 2011 net loss was $953,936, versus $2.53 million in 2010. After a $100,000 deemed preferred-stock dividend, loss attributable to common stockholders was $1.05 million in 2011, or $0.07 per share, versus $2.53 million, or $0.16 per share, in 2010.
- Expenses: SG&A was $827,674, down $1.48 million year over year; R&D was $111,554, down $83,034. Management attributed the decreases mainly to suspended operations, payroll cuts and reduced clinical activity. The 2010 SG&A included approximately $416,000 of one-time former-CEO separation costs.
- Cash flow: Operating cash use was $291,160 in 2011 versus $2.30 million in 2010. Financing provided $145,858 in 2011, including preferred-stock proceeds and related-party advances. Cash declined to $146,160 at year-end from $291,462.
- Liquidity: Current assets were $160,957 and current liabilities were $1.86 million at December 31, 2011, a working-capital deficit of approximately $1.70 million. The auditor cited recurring losses, negative operating cash flows and the deficit as raising substantial doubt about the company’s ability to continue as a going concern.
- Debt: Year-end liabilities included a $300,000 related-party line-of-credit borrowing and a $1.13 million current convertible note balance, including accrued interest. The related-party facility allowed advances up to $750,000 and bore 10% interest; the company pledged all assets, including intellectual property, as security.
- Margins: Not meaningful because the company had no revenue.
Material changes and unusual items
- The company filed for Chapter 11 in June 2011; the court denied its proposed asset sale to Cardium, and the bankruptcy case was dismissed in December 2011.
- After dismissal, DermaStar provided a secured credit facility and purchased Series A preferred stock for $100,000. The preferred shares carried voting and conversion rights that gave DermaStar control; related-party interests include company directors and executives.
- In January 2012, holders of the 7.5% convertible note agreed to waive certain rights and convert their balances when sufficient common shares were authorized. The filing estimated that note and accounts-payable conversions could issue approximately 73.3 million additional common shares; a separate preferred-stock conversion could also be highly dilutive.
- The company settled former employees’ priority claims with cash and options, recognizing a $60,292 gain from forgiven liabilities.
- Management disclosed ineffective disclosure controls and internal control over financial reporting, citing insufficient segregation of duties and weakly documented governance processes.
Outlook, risks and contingencies
- Management estimated it needed an additional $6 million to execute its 2012 plan, including further Ketotransdel development. It had no financing arrangements beyond the DermaStar line and warned that failure to raise funds could force it to cease operations.
- Management forecast available cash could support only part of its operating plan through the third quarter of 2012; the auditor’s going-concern paragraph and liquidity disclosures emphasize that financing was uncertain.
- The Phase 3 trial enrolled 364 patients but failed its primary endpoint in the original analysis. A post-hoc modified analysis excluding 35 ineligible randomized patients showed statistical significance; FDA discussions indicated at least two additional adequate and well-controlled Phase 3 trials and supportive safety studies would be needed. Initiation was contingent on financing, with management citing 2012 or 2013 as a possible timeframe.
- Two cosmetic-product license arrangements were terminated or expected to be terminated after partners abandoned commercialization efforts. The company had received $100,000 in nonrefundable royalty advances, recorded as deferred revenue at year-end.
- Further risks include regulatory and clinical uncertainty, reliance on third-party contractors, limited staffing, competition, patent protection expiring in 2016 absent extension, and substantial dilution and concentrated voting control.
Investor facts to verify
- Confirm the filing is the intended issuer and period: the document identifies Transdel Pharmaceuticals, Inc., fiscal 2011—not Harrow, Inc. or 2010 Q4.
- Verify current cash, liquidity runway, access to remaining credit availability and the status and terms of any subsequent financing.
- Confirm the effective status of the authorized-share increase, one-for-eight reverse split, company name change and preferred-stock and note conversions.
- Assess the actual dilution and voting control resulting from convertible securities, related-party debt and expanded equity-plan awards.
- Track FDA feedback, financing, trial design and timing for the required Ketotransdel studies, bearing in mind the original Phase 3 primary-endpoint failure.
- Review remediation of the disclosed control weaknesses and any updated going-concern assessment.